logo
logo
Sign in

Biopharma Buffer Market Is Estimated To Witness High Growth Owing To Demand For Protein Therapeutics

avatar
kiran gire
Biopharma Buffer Market Is Estimated To Witness High Growth Owing To Demand For Protein Therapeutics

The biopharma buffer market plays a vital role in pharmaceutical and biopharmaceutical research and manufacturing. Buffers help regulate and stabilize pH levels of protein therapeutics and cell culture media to support optimal cell growth and protein expression. They help maintain an optimal pH range for formulation, filling, transportation and storage of biologics.

The global Biopharma Buffer Market is estimated to be valued at US$ 3.68 billion in 2024 and is expected to exhibit a CAGR of 11% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Opportunity:

Demand for Protein Therapeutics

The demand for protein therapeutics like monoclonal antibodies, vaccines and recombinant proteins is growing rapidly owing to their effectiveness in treating diseases such as cancer, diabetes and cardiovascular diseases. According to estimates, monoclonal antibodies currently account for over 50% of global biopharma R&D pipelines. With the increasing approvals and commercialization of novel protein drugs, the demand for associated buffers is also expected to rise significantly over the forecast period. This growing demand for protein therapeutics presents a major market opportunity for players in the biopharma buffer market.

Porter's Analysis

Threat of new entrants: The biopharma buffer market faces relatively moderate threat of new entrants due to requirements for research and development expenditure to comply with strict quality and regulatory standards.

Bargaining power of buyers: Large biopharmaceutical companies have significant bargaining power over buffer suppliers due to their scale and ability to pressure on price.

Bargaining power of suppliers: A few global players dominate supply in this market, giving them strong bargaining power over buyers.

Threat of new substitutes: There is low threat of substitution given the crucial role of buffers in biopharmaceutical processes where consistency and stability are critical factors.

Competitive rivalry: The market is highly competitive with established global players continuously investing in product innovation and expansion to biologics manufacturing regions like Asia Pacific and Latin America.

SWOT Analysis

Strengths: The biopharma buffer market benefits from strong demand driven by the large and growing biopharmaceutical industry. Leading players have established global manufacturing and supply chain networks.

Weaknesses: Biopharma buffers have stringent quality and certification standards requiring substantial R&D expenditures limiting entry of small players. Dependence on few suppliers also impacts buyer flexibility.

Opportunities: Growth in biologics outsourcing and Asia's emerging role as a key biologics hub present opportunities for localized buffer production. Advanced offerings like customized solutions tailored for specific bioprocessing needs could boost growth.

Threats: Stringent regulations governing the biopharmaceutical industry can delay new product approvals and market entry. Consolidation among buffer suppliers reduces buyer options.

Key Takeaways

The global biopharma buffer market scope is expected to witness high growth over the forecast period of 2023 to 2030. The market size is projected to reach US$ 3.68 Billion by 2024.

Regional analysis: The Asia Pacific region is expected to be the fastest growing market for biopharma buffers during the forecast period. This is attributed to increasing investments by manufacturers to establish production facilities in emerging Asian countries like India and China due to availability of low-cost skilled workforce. Countries like China and India are also witnessing significant market growth due to rising local biologics production. North America currently dominates the global market due to presence of major players and a well-established biopharmaceutical industry.

Key players: Key players operating in the biopharma buffer market are Digital Medics Pty. Ltd., Emperra GmbH E-Health Technologies, Bio-Rad Laboratories Inc., Sartorius AG, Avantor Inc., and Merck KGaA. These players are focusing on expanding their manufacturing capabilities and product portfolio through acquisitions and new product launches to better serve the growing demand. For instance, in 2022, Sartorius AG acquired cell culture media brand Biological Industries to enhance its media and buffer offerings for cell and gene therapy applications.

Get more insights on this topic: https://www.trendingwebwire.com/biopharma-buffer-market-industry-insights-trends-biopharma-buffer-market/

Explore more information on this topic, Please visit: https://filmik.in/design-brilliance-unleashed-elevate-brands-with-the-expert-packaging-design-services/


collect
0
avatar
kiran gire
guide
Zupyak is the world’s largest content marketing community, with over 400 000 members and 3 million articles. Explore and get your content discovered.
Read more